SMM also shows an M protein on SPEP and is similar to MGUS in its lack of clinical manifestations but is more likely to progress to symptomaticmyeloma; progression to MM is 10% per year for the first 5 years, 3% per year for the subsequent 5 years, and 2% per year for the 5 years...
NCCN Guidelines Version 2.2023 Multiple Myeloma NCCN Guidelines Index Table of Contents Discussion INITIAL DIAGNOSTIC WORKUPa CLINICAL FINDINGS • History and physical (H&P) exam Useful In Certain Circumstances • CBC, di erential, and platelet count • If whole-body low-dose CT or FDG PET/...
Education Lab | CME | This monograph discusses new agents that are being introduced for relapsed/refractory multiple myeloma and the role these agents are likely to play when they become commercially available in the United States. Optimal induction therapy is also reviewe...
A stem cell transplant is a common treatment for multiple myeloma. If you’re able to have one, you’ll get induction therapy followed by a high dose of a chemotherapy drug to kill as many cancer cells as possible. Or your doctor might give you a combination of some of the other medici...
The incidence of multiple myeloma (MM), a type of blood cancer affecting monoclonal plasma cells, is rising. Although new drugs and therapies have improved patient outcomes, MM remains incurable. Recent studies have highlighted the crucial role of the ch
Discover KYPROLIS®, a multiple myeloma treatment option for people who have already received 1 or more previous treatments. See Full Safety & Prescribing Info.
Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapyAnti-thymocyte globulin (ATG) is used as prophylaxis against graft-versus-host-disease (GVHD). Current dosing regimens for ATG are empiric, weight-...
Based on these findings, we hypothesize that MYC-proficient MM cells downregulate miR-22 levels to amplify MYC-driven myelomagenesis by promoting cell survival and escape from NK cytotoxic activity. However, at the same time, these events make MM cells more vulnerable to increased expression of ...
Minimal residual disease (MRD) status is now considered as one of the most relevant prognostic factors in multiple myeloma (MM) while MRD negativity became an important endpoint in clinical trials. Here, we report the results of the first study evaluating the reproducibility of high-sensitivity flo...
名称:RosetteSep™ Human Multiple Myeloma Cell Enrichment Cocktail 规格:For processing 40mL/200mL bone marrow 产品描述:Immunodensity negative selection cocktail 购买数量: 立即购买 产品信息 The RosetteSep™ Human Multiple Myeloma Cell Enrichment Cocktail is designed to enrich multiple myeloma cells (B ce...